Global Blockbuster Drugs Industry
According to the latest report added to the online repository of Wise Guys Reports (WGR) the Global Blockbuster Drugs market has witnessed an unprecedented rise and the extrapolated growth is expected to touch $292 billion by 2025 registering a more than average CAGR.
Try Sample of Global Blockbuster Drugs Market @ https://www.wiseguyreports.com/sample-request/3602067-global-blockbuster-drugs-market-2015-2025-top-50
Medications that generate more than $1 billion in revenue in a year for their respective pharmaceutical companies are termed as Blockbuster drugs. Most of the pharmaceutical companies register profit aided by the right collaboration of time, work and effort put in developing these new drugs which is indispensable to their success. Thus if a drug is elevated to the level of blockbuster drug then it becomes a matter of great achievement and accomplishment for the pharmaceutical companies and their investors. Although due to the patent laws the live span of the success is usually short-lived for these blockbuster drugs. This puts doubt and unreliability in the revenue generated by the pharmaceuticals through the production of new drugs.
As of 2005 the global pharmaceutical market was valued at $600 billion out of which 60% of the $245 billion in earnings of top 10 pharmaceuticals was attributed to successful medication. But most of the currently high revenue generating drugs will face patent expiration in the coming few years which could result in diminishing sales figures. The reason of decreasing number of blockbuster drugs in the market over the years can be divided into two major reasons. Firstly stringent regulations and guidelines have resulted into fewer numbers of drugs qualifying for US FDA approval. Secondly, negligence on part of the pharmaceutical companies in their research and development sector resulting into poor drugs that is not able to meet US FDA recommended standards. However according to the Pharmaceutical Research and Manufacturers of America more money is funnelled into R&D with a 65% increase in budget spent on research and development in 2006 as compared to 2000. This makes pharmaceutical sector as the most research oriented sector in US.
The report provides insight into global blockbuster drugs market dynamics and opportunities by laying the future roadmap and focusing on the competitive landscape and major trends. Most current market study along with in-depth analysis is included as part of the report to offer better and comprehensive view.
Global Blockbuster Drugs Market: Major Players
Using business overview and recent developmental progress as the pivotal points the major players of the market is recognized.
The major companies in terms of generating revenue are AbbVie, Bayer, Regeneron Pharmaceuticals, Novo Nordisk, Allergan, Celgene, Gilead Science, Astrazeneca, Incyte Corporation Merck, Roche, Bristol–Myers Squibb, Pfizer, Johnson & Johnson, Amgen, Biogen,, Alexion Pharmaceuticals, GlaxoSmithKline, Novartis, Eli Lilly and Company, Boehringer Ingelheim & Astellas Pharma.
Global Blockbuster Drugs Market: Top 50 Drugs
The top 50 Blockbuster drugs in the market are Humira, Jakafi,Jakavi, Jardiance, Trajenta , Jentadueto & Relvar, Imbruvica, Revlimid, Genvoya, Truvada, Harvoni, Epclusa, Keytruda, Januvia,Janumet, Herceptin, Triumeq, Seretide,Advair, Gilenya, Cosentyx, Trulicity, Cialis, Humalog, Symbicort, Zepatier, Avastin, MabThera,Rituxan, Perjeta, Opdivo, Eliquis, Orencia, Sprycel, Lyrica, Ibrance, Simponi, Stelara, Zytiga, Invega Sustenna, Xarelto, Enbrel, Tagrisso, Tecfidera, Eylea, Victoza, Botox, Soliris, Pomalyst,Imnovid, Darzalex, Prolia,Xgeva, Ocrevus, Xtandi, Tivicay, Breo Ellipta.
For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3602067-global-blockbuster-drugs-market-2015-2025-top-50
For more information or any query mail at email@example.com
Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
+1 646 845 9349 / +44 208 133 9349